There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD117


CD117 Molecule Information

Name:Stem cell growth factor receptor
Target Synonym:Proto-oncogene c-Kit;CD_antigen=CD117;Tyrosine-protein kinase Kit;SCFR;Mast/stem cell growth factor receptor Kit;v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;PBT;Piebald trait protein;p145 c-kit;KIT
Number of Launched Drugs:13
Number of Drugs in Clinical Trials:30
Lastest Research Phase:Approved

CD117 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CD7-H5255 Human Human CD117 / c-kit Protein, Fc Tag
CD7-H52H4 Human Human CD117 / c-kit Protein, His Tag

CD117 Molecule Synonym Name


CD117 Molecule Background

Mast/stem cell growth factor receptor Kit (c-Kit), a member of the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily, is also known as piebald trait protein (PBT), p145 c-kit, tyrosine-protein kinase Kit and CD117,which contains five Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. CD117 acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, CD117 can activate several signaling pathways. Furthermore, Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B.

CD117 References

CD117 Related Molecule


CD117 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Anlotinib Dihydrochloride AL-3818 Approved Chiatai Tianqing (CTTQ), Advenchen Laboratories Anlotinib Hydrochloride Capsules cfda Non small cell lung cancer (NSCLC), Soft tissue sarcoma, Small cell lung cancer (SCLC) 2018-05-08 Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Soft tissue sarcoma Details
Ancestim AMJ-9302 Approved Amgen, SOBI Stem cell mobilization Details
Imatinib mesylate STI-571; CGP-57148B; CGP-57148; CTI-571; QTI-571,CGP57148B,STI 571,STI571,CGP 57148B Approved Novartis GLEEVEC fda Gastrointestinal stromal tumors (GISTs), Chronic myeloid leukemia (CML ) NOVARTIS 2001-05-10 Myelodysplastic syndrome (MDS), Myeloproliferative Disorders (MPD), Gastrointestinal stromal tumors (GISTs), Aggressive systemic mastocytosis (ASM), Hypereosinophilic syndrome (HES), Dermatofibrosarcoma protuberans (DFSP), Chronic eosinophilic leukemia (CEL), Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) Details
Sorafenib Tosylate BAY-54-9085; BAY-43-9006; BAY-43-0006; NSC-724772,BAY 43-9006,BAY54-9085,BAY43-9006,BAY 54-9085 Approved Onyx Pharmaceutical, Bayer NEXAVAR fda Differentiated thyroid cancer, Advanced renal cell carcinoma (RCC), Unresectable hepatocellular carcinoma BAYER HLTHCARE 2005-12-01 Differentiated thyroid cancer, Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Unresectable hepatocellular carcinoma, Hepatocellular carcinoma (HCC) Details
Regorafenib Monohydrate BAY-73-4506; DAST,BAY73-4506,BAY 73-4506,BAY-734506 Approved Bayer, Onyx Pharmaceutical STIVARGA fda Gastrointestinal stromal tumors (GISTs), Metastatic colorectal cancer (CRC) BAYER HLTHCARE 2012-09-27 Gastrointestinal stromal tumors (GISTs), Liver cancer, Metastatic colorectal cancer (CRC), Hepatocellular carcinoma (HCC) Details
Pexidartinib PLX-3397 Approved Daiichi Sankyo TURALIO fda Tenosynovial giant cell tumor (TGCT) DAIICHI SANKYO INC 2019-08-02 Tenosynovial giant cell tumor (TGCT) Details
Lenvatinib Mesylate E-7080; ER-203492-00,E7080 Approved Eisai LENVIMA fda Thyroid cancer EISAI INC 2015-02-13 Differentiated thyroid cancer, Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Thyroid cancer, Unresectable hepatocellular carcinoma, Hepatocellular carcinoma (HCC) Details
Sunitinib Malate PNU-290940; SU-11248; SU-010398; SU-011248-L-malate salt; PHA-290940; PHA-290940AD; PNU-290940AD; GB-102,SU11248,PNU 290940,PNU290940,SU 11248 Approved Pfizer SUTENT fda CPPI CV 2006-01-26 Renal cell carcinoma, Gastrointestinal stromal tumors (GISTs), Advanced renal cell carcinoma (RCC), Pancreatic neuroendocrine tumors (pNET), Renal carcinoma Details
Ponatinib Hydrochloride AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; INCB-84344,AP 24534,AP24534 Approved Ariad ICLUSIG fda Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) ARIAD 2012-12-14 Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) Details
Avapritinib BLU-285,BLU-285; CS-3007 Approved Blueprint Medicines, CStone Pharmaceuticals AYVAKIT fda BLUEPRINT MEDICINES CORP 2020-01-09 Gastrointestinal stromal tumors (GISTs) Details
Cabozantinib S-malate XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351 Approved Exelixis, Ipsen, Takeda COMETRIQ fda Medullary thyroid cancer (MTC) EXELIXIS 2012-11-29 Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC) Details
Pazopanib Hydrochloride GW-786034; GSK-786034; GW-786034B ; SB-786034,GW786034,GW 786034 Approved GlaxoSmithKline, Novartis VOTRIENT fda Renal cell carcinoma, Soft tissue sarcoma NOVARTIS 2009-10-19 Renal cell carcinoma, Soft tissue sarcoma, Soft tissue infections, Renal carcinoma Details
Midostaurin PKC-412; CGP-41231; CGP-41251; PKC-412A Approved Novartis RYDAPT fda Systemic mastocytosis with associated hematological neoplasm, Aggressive systemic mastocytosis (ASM), Acute myeloid Leukemia (AML), Mast cell leukemia NOVARTIS 2017-04-28 Systemic mastocytosis with associated hematological neoplasm, Aggressive systemic mastocytosis (ASM), Acute myeloid Leukemia (AML), Mast cell leukemia Details
Dasatinib Hydrate BMS-354825; NSC-732517 ,BMS354825,BMS 354825 Approved Bristol-Myers Squibb SPRYCEL fda Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) BRISTOL MYERS SQUIBB 2006-06-28 Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) Details

CD117 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Subutinib Maleate Phase Ⅰ Chiatai Tianqing (CTTQ), China State Institute of Pharmaceutical Industry (CSIPI) Gastrointestinal stromal tumors (GISTs), Renal cell carcinoma, Breast cancer, Ovarian cancer, Pancreatic cancer Details
PLX-9486 PLX-9486 Phase Ⅱ Daiichi Sankyo Gastrointestinal stromal tumors (GISTs), Solid tumours Details
Anti-c-kit humanised IgG1/κ antibody-maitansine conjugate (Novartis) LOP-628 Phase Ⅰ Novartis Solid tumours, Acute myeloid Leukemia (AML) Details
Famitinib Malate SHR-1020 Phase Ⅲ Jiangsu Hengrui Medicine Non small cell lung cancer (NSCLC), Colorectal cancer Details
Vatalanib succinate CGP-79787D; PTK-787; ZK-222584 Phase Ⅲ Novartis, Bayer Colorectal cancer Details
Amuvatinib MP-470; HPK-56,MP470,HPK56 Phase Ⅱ Astex Pharmaceuticals Small cell lung cancer (SCLC) Details
SU-014813 SU-014813; SU-14813 Phase Ⅱ Pfizer Breast cancer Details
Telatinib BAY-57-9352; EOC-315 Phase Ⅱ Bayer, Eddingpharm Gastric cancer, Solid tumours Details
Golvatinib/Lenvatinib Phase Ⅱ Eisai Glioblastoma, Angiomas, Melanoma Details
Tafetinib Malate SIM-010603; SIM-0702; SIM-1005,SIM010603 Phase Ⅰ Simcere, BolDere Pharma, Nanjing Yoko Biological Colon cancer, Non small cell lung cancer (NSCLC), Gastrointestinal stromal tumors (GISTs), Renal cell carcinoma, Breast cancer, Liver cancer, Ovarian cancer Details
Tandutinib MLN-0518; MLN-518; CT-53518,MLN0518,MLN518,CT53518 Phase Ⅱ Takeda Renal cell carcinoma, Acute myeloid Leukemia (AML) Details
QBH-196 QBH-196 Phase Ⅰ Shenyang Pharmaceutical University Gastric cancer Details
Imatinib mesylate (YD Global Life Science) YD-312 Phase Ⅱ YD Global Life Science Diabetic macular edema Details
Dovitinib CHIR-258; GFKI-258; CHIR-258LC; TKI-258; NVP-TKI258,GFKI258,CHIR258,TKI258 Phase Ⅲ Novartis Renal cell carcinoma, Solid tumours Details
Motesanib Diphosphate AMG-706,AMG706,AMG 706 Phase Ⅲ Amgen, Takeda Advanced non-squamous non small cell lung cancer (NSCLC) Details
QLNC-3A6 Di-Maleate Phase Ⅰ Qilu Pharmaceutical, Qilu Antibiotics (Linyi) Pharmaceutical Solid tumours Details
Masitinib mesylate AB-1010 NDA Filing AB Science Systemic mastocytosis with associated hematological neoplasm, Amyotrophic lateral sclerosis (ALS) Details
AKN-028 AKN-028; BVT-II; BVT-63628 ,AKN028,BVTII,BVT63628 Phase Ⅱ Akinion Acute myeloid Leukemia (AML) Details
IGN-311 IGN-311 Phase Ⅰ PDL BioPharma, Celltrion Cancer Details
Hydroxychloroquine/Sorafenib Phase Ⅰ VG Life Sciences Solid tumours, Ovarian cancer Details
Donafenib Tosylate CM-4307 Phase Ⅲ Zelgen Biosciences Thyroid cancer, Colorectal cancer Details
FSI-174 FSI174,FSI-174 Preclinical Forty Seven hematological malignancies Details
Sorafenib/MG-005 MGD-1509 Phase Ⅱ Metagone Biotech, The General Hospital of the Three Armies Solid tumours Details
Thiophenib Tosylate SIM-81; OSI-930 Phase Ⅰ Astellas, Simcere Small cell lung cancer (SCLC), Gastric cancer, Non small cell lung cancer (NSCLC), Colorectal neoplasms, Gastrointestinal stromal tumors (GISTs), Esophagus cancer, Ovarian cancer, Head and neck cancer, Malignant glioma Details
Lapatinib/Pazopanib Phase Ⅲ GlaxoSmithKline Renal cell carcinoma Details
NMS-03592088 NMS-03592088; NMS-P088 Phase Ⅱ Nerviano Medical Sciences Acute myeloid Leukemia (AML), Chronic myeloid leukemia (CML ) Details
XL-820 XL-820 Phase Ⅱ Exelixis Gastrointestinal stromal tumors (GISTs) Details
mSCF-based gene therapy (Celladon) Preclinical Celladon ischaemic heart disorder Details
Ripretinib DCC-2618 NDA Filing Deciphera, Zai Lab Gastrointestinal stromal tumors (GISTs), Aggressive systemic mastocytosis (ASM), Malignancies Details
AG-2034 AG-2034; AGL-2034 Phase Ⅰ Yissum Solid tumours Details

This web search service is supported by Google Inc.